BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 38715180)

  • 1. Phosphatidylserine and Tyro3-Axl-Mertk Receptor Tyrosine Kinase level detection in plasma and on plasma-derived extracellular vesicle surface in chronic lymphocytic leukemia.
    Bay M; Seval GC; Coskun O; Gurman G; Erdas NO
    Cell Biochem Funct; 2024 Jun; 42(4):e4035. PubMed ID: 38715180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
    Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
    Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression.
    Kasikara C; Kumar S; Kimani S; Tsou WI; Geng K; Davra V; Sriram G; Devoe C; Nguyen KN; Antes A; Krantz A; Rymarczyk G; Wilczynski A; Empig C; Freimark B; Gray M; Schlunegger K; Hutchins J; Kotenko SV; Birge RB
    Mol Cancer Res; 2017 Jun; 15(6):753-764. PubMed ID: 28184013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation.
    Zhou J; Yang A; Wang Y; Chen F; Zhao Z; Davra V; Suzuki-Inoue K; Ozaki Y; Birge RB; Lu Q; Wu Y
    Cell Commun Signal; 2018 Dec; 16(1):98. PubMed ID: 30541554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.
    Sinha S; Boysen J; Nelson M; Secreto C; Warner SL; Bearss DJ; Lesnick C; Shanafelt TD; Kay NE; Ghosh AK
    Clin Cancer Res; 2015 May; 21(9):2115-26. PubMed ID: 25673699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor tyrosine kinases Tyro3, Axl, and Mertk differentially contribute to antibody-induced arthritis.
    Gao L; He C; Yang A; Zhou H; Lu Q; Birge RB; Wu Y
    Cell Commun Signal; 2023 Aug; 21(1):195. PubMed ID: 37537628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.
    Ghosh AK; Secreto C; Boysen J; Sassoon T; Shanafelt TD; Mukhopadhyay D; Kay NE
    Blood; 2011 Feb; 117(6):1928-37. PubMed ID: 21135257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities.
    Lew ED; Oh J; Burrola PG; Lax I; Zagórska A; Través PG; Schlessinger J; Lemke G
    Elife; 2014 Sep; 3():. PubMed ID: 25265470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment.
    Myers KV; Amend SR; Pienta KJ
    Mol Cancer; 2019 May; 18(1):94. PubMed ID: 31088471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Interaction of Platelet-Derived Extracellular Vesicles With Circulating Immune Cells: Roles of TAM Receptors, CD11b, and Phosphatidylserine.
    Fendl B; Eichhorn T; Weiss R; Tripisciano C; Spittler A; Fischer MB; Weber V
    Front Immunol; 2018; 9():2797. PubMed ID: 30619243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAM receptors: A phosphatidylserine receptor family and its implications in viral infections.
    Ghosh Roy S
    Int Rev Cell Mol Biol; 2020; 357():81-122. PubMed ID: 33234246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders.
    Gadiyar V; Patel G; Chen J; Vigil D; Ji N; Campbell V; Sharma K; Shi Y; Weiss MM; Birge RB; Davra V
    Front Immunol; 2023; 14():1135373. PubMed ID: 37545504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
    Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
    Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
    McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
    Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-3 Stimulates Tyro3 Receptor Tyrosine Kinase and Erk Signalling, Cell Survival and Migration in Human Cancer Cells.
    Al Kafri N; Hafizi S
    Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32664510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.
    Graham DK; DeRyckere D; Davies KD; Earp HS
    Nat Rev Cancer; 2014 Dec; 14(12):769-85. PubMed ID: 25568918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation.
    Tsou WI; Nguyen KQ; Calarese DA; Garforth SJ; Antes AL; Smirnov SV; Almo SC; Birge RB; Kotenko SV
    J Biol Chem; 2014 Sep; 289(37):25750-63. PubMed ID: 25074926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer effect of luteolin is mediated by downregulation of TAM receptor tyrosine kinases, but not interleukin-8, in non-small cell lung cancer cells.
    Lee YJ; Lim T; Han MS; Lee SH; Baek SH; Nan HY; Lee C
    Oncol Rep; 2017 Feb; 37(2):1219-1226. PubMed ID: 28035396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer.
    Uribe DJ; Mandell EK; Watson A; Martinez JD; Leighton JA; Ghosh S; Rothlin CV
    PLoS One; 2017; 12(7):e0179979. PubMed ID: 28727830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axl and MerTK receptor tyrosine kinases maintain human macrophage efferocytic capacity in the presence of viral triggers.
    Grabiec AM; Goenka A; Fife ME; Fujimori T; Hussell T
    Eur J Immunol; 2018 May; 48(5):855-860. PubMed ID: 29400409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.